Answers are grounded in this paper and cite their sources.
Identifies novel inhibitors of Mycobacterium tuberculosis in plant extracts, indicating dual-targeting mechanisms.
Abstract (±)-Hypericandrone A (HCA, 1), an unprecedented pair of enantiomeric polycyclic polyprenylated acylphloroglucinols (PPAPs), and its biosynthetic congener hypericandrone B (HCB, 2) were isolated from the fruits of Hypericum androsaemum. Compound 1 features a unique 2-cyclopentane-bicyclo[3.3.0]octane scaffold, while 2 possesses a rare 2-cyclopentyltetrahydrofuran framework. Their absolute configurations were unequivocally determined by spectroscopic analysis, single-crystal X-ray diffraction, and ECD calculations. Remarkably, (+)-1 displayed potent antitubercular activity by selectively inhibiting the acetyltransferase domain of Mycobacterium tuberculosis GlmU through a dual mechanism, acting competitively against acetyl-CoA (Ki = 0.07 μM) and noncompetitively against glucosamine-1-phosphate (GlcN-1-P, Ki = 0.20 μM).
No takes yet. Share an insight, caveat, or question.
Wei et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: